Ultomiris

Chemical Nameravulizumab
Dosage FormInjection (intravenous; 300 mg/30 mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyAlexion Pharmaceuticals Inc.
Approval Year2018

Indication

  • To treat paroxysmal nocturnal hemoglobinuria in adults. •
  • To treat atypical hemolytic uremic syndrome in patients ≥ 1 month of age.
Last updated on 11/5/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ultomiris (Ravulizumab) Prescribing Information 2018Alexion Pharmaceuticals, Inc., Boston, MA